eledon-logo-1230.png
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
12. November 2024 16:01 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
06. November 2024 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
29. Oktober 2024 07:45 ET | Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11. September 2024 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
eledon-logo-1230.png
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
14. August 2024 17:21 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
eledon-logo-1230.png
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
29. Juli 2024 07:00 ET | Eledon Pharmaceuticals, Inc.
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
eledon-logo-1230.png
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
02. Juli 2024 16:05 ET | Eledon Pharmaceuticals, Inc.
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
eledon-logo-1230.png
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03. Juni 2024 16:01 ET | Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
eledon-logo-1230.png
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
09. Mai 2024 07:30 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
eledon-logo-1230.png
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
09. Mai 2024 07:00 ET | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024